Boxer Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Boxer Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$14.6M	–	62
2023 Q3	$14.6M	Hold	100,000	–	–	0.78%	38
2023 Q2	$23.1M	Buy	+100,000	New	+$27.1M	1.07%	32
2018 Q3	–	Sell	-95,000	Closed	-$26.6M	–	25
2018 Q2	$26.6M	Buy	+95,000	New	+$16.7M	3.01%	13

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital's MDGL Position: Q4 2023 in Review

Boxer Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 100,000 shares — an estimated $14.6M sold.

Boxer Capital first reported a position in MDGL in Q2 2018 and held it in 3 quarters. The position peaked at $26.6M in Q2 2018. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

Boxer Capital reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Boxer Capital sold 100,000 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $14.6M.
Boxer Capital first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 3 quarters.
Boxer Capital's Madrigal Pharmaceuticals position peaked at $26.6M in Q2 2018.
226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.